DUBLIN – The contest to develop new therapeutics targeting transforming growth factor beta 1 (TGF-beta1) signaling in cancer intensified this week, as both Abbvie Inc. and Scholar Rock Holding Corp.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback